• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用力肺活量呈边际下降与特发性肺纤维化的不良预后相关。

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.

机构信息

Royal Brompton Hospital and National Heart and Lung Institute, London, UK.

出版信息

Eur Respir J. 2010 Apr;35(4):830-6. doi: 10.1183/09031936.00155108. Epub 2009 Oct 19.

DOI:10.1183/09031936.00155108
PMID:19840957
Abstract

In therapeutic studies in idiopathic pulmonary fibrosis (IPF), the low prevalence of significant change in pulmonary functional tests (PFTs) has been a major constraint. The prognostic value of "marginal" changes in PFTs in IPF and fibrotic non-specific interstitial pneumonia (NSIP) was evaluated. In patients with biopsy-proven IPF (n = 84) and NSIP (n = 72), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (D( L,CO)) trends at 6 months were categorised as "significant" (FVC >10%; D(L,CO) >15%) or "marginal" (FVC 5-10%; D(L,CO) 7.5-15%). Proportional hazards analysis and time-dependent receiver operating characteristic methodology were used to examine PFT trends against mortality. In IPF, reductions in FVC were significant in 22 cases (26%) and marginal in 19 cases (23%). Mortality was higher in patients with a significant decline in FVC (hazard ratio (HR) 2.80, 95% CI 1.54-5.06; p<0.001) and those with a marginal decline in FVC (HR 2.31, 95% CI 1.19-4.50; p = 0.01) than in those with stable disease. Progression-free survival was lower when the decline in FVC was marginal than in stable disease (HR 2.34, 95% CI 1.19-4.60; p = 0.01). Marginal changes in D(L,CO) in IPF and marginal changes in FVC and D (L,CO) in fibrotic NSIP did not provide useful prognostic information. Marginal change in FVC in IPF denotes a poor outcome. These findings are applicable to clinical practice and to the selection of patients with more progressive disease for therapeutic studies.

摘要

在特发性肺纤维化(IPF)的治疗研究中,肺功能测试(PFT)中显著变化的低发生率一直是一个主要限制。评估了 IPF 和纤维化非特异性间质性肺炎(NSIP)中 PFT“边缘”变化的预后价值。在经活检证实的 IPF 患者(n = 84)和 NSIP 患者(n = 72)中,6 个月时用力肺活量(FVC)和一氧化碳弥散量(D(L,CO))趋势被分类为“显著”(FVC >10%;D(L,CO)>15%)或“边缘”(FVC 5-10%;D(L,CO)7.5-15%)。比例风险分析和时间依赖的接收器操作特性方法用于检查 PFT 趋势与死亡率之间的关系。在 IPF 中,FVC 下降在 22 例(26%)中为显著,在 19 例(23%)中为边缘。FVC 显著下降的患者死亡率更高(风险比(HR)2.80,95%置信区间 1.54-5.06;p<0.001)和 FVC 边缘下降的患者(HR 2.31,95%置信区间 1.19-4.50;p = 0.01)高于稳定疾病的患者。FVC 下降边缘时无进展生存率低于稳定疾病(HR 2.34,95%置信区间 1.19-4.60;p = 0.01)。IPF 中 D(L,CO)的边缘变化和纤维化 NSIP 中 FVC 和 D(L,CO)的边缘变化并不能提供有用的预后信息。IPF 中 FVC 的边缘变化表示预后不良。这些发现适用于临床实践和为治疗研究选择更具进展性疾病的患者。

相似文献

1
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.用力肺活量呈边际下降与特发性肺纤维化的不良预后相关。
Eur Respir J. 2010 Apr;35(4):830-6. doi: 10.1183/09031936.00155108. Epub 2009 Oct 19.
2
Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.新诊断的特发性肺纤维化患者用力肺活量的变化及相关后续结局
BMC Pulm Med. 2015 Dec 29;15:167. doi: 10.1186/s12890-015-0161-5.
3
A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis.呼吸困难的简易评估作为特发性肺纤维化的预后指标。
Eur Respir J. 2010 Nov;36(5):1067-72. doi: 10.1183/09031936.00152609. Epub 2010 Apr 22.
4
Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis.特发性肺纤维化初始评估中肺动脉高压作为预后指标。
Respiration. 2013;85(6):456-63. doi: 10.1159/000345221. Epub 2012 Dec 19.
5
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.系统性硬化症患者肺纤维化的组织病理学亚组及其与预后的关系。
Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581-6. doi: 10.1164/rccm.2106012.
6
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者用力肺活量急性加重和下降与死亡率升高相关。
Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.
7
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.特发性肺纤维化患者的用力肺活量:测试特性和最小临床重要差异。
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9. doi: 10.1164/rccm.201105-0840OC. Epub 2011 Sep 22.
8
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者个体死亡率风险的确定。
Am J Respir Crit Care Med. 2011 Aug 15;184(4):459-66. doi: 10.1164/rccm.201011-1790OC.
9
Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis.特发性肺纤维化合并肺气肿可延缓肺活量的下降。
Respir Med. 2009 Aug;103(8):1209-15. doi: 10.1016/j.rmed.2009.02.001. Epub 2009 Feb 28.
10
Clinical and functional outcomes in Middle Eastern patients with idiopathic pulmonary fibrosis.中东地区特发性肺纤维化患者的临床及功能转归
Clin Respir J. 2008 Oct;2(4):220-6. doi: 10.1111/j.1752-699X.2008.00070.x.

引用本文的文献

1
Radiomics derived from HRCT can predict mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis.源自高分辨率计算机断层扫描(HRCT)的影像组学能够预测特发性肺纤维化急性加重患者的死亡率。
J Thorac Dis. 2025 Jul 31;17(7):4990-5001. doi: 10.21037/jtd-2025-194. Epub 2025 Jul 25.
2
Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases.间质性肺疾病的病理生理见解与临床管理策略
Biomol Ther (Seoul). 2025 Sep 1;33(5):785-803. doi: 10.4062/biomolther.2025.003. Epub 2025 Aug 14.
3
The potential clinical implications of slow vital capacity in patients with idiopathic pulmonary fibrosis.
特发性肺纤维化患者慢肺活量的潜在临床意义。
Respir Res. 2025 Jul 2;26(1):228. doi: 10.1186/s12931-025-03304-8.
4
Systemic autoimmune rheumatic diseases-associated interstitial lung disease: a pulmonologist's perspective.系统性自身免疫性风湿性疾病相关间质性肺疾病:肺科医生的观点
Breathe (Sheff). 2025 Jun 17;21(2):240171. doi: 10.1183/20734735.0171-2024. eCollection 2025 Apr.
5
Serum IgA levels and survival in patients with idiopathic pulmonary fibrosis: association with serum cytokine levels and peripheral monocyte counts.特发性肺纤维化患者的血清IgA水平与生存率:与血清细胞因子水平及外周血单核细胞计数的关联
J Thorac Dis. 2025 Apr 30;17(4):2038-2049. doi: 10.21037/jtd-2024-2142. Epub 2025 Apr 28.
6
Relationships between disease severity and measures of health status in people with interstitial lung disease in India: an observational study.印度间质性肺疾病患者疾病严重程度与健康状况指标之间的关系:一项观察性研究。
Sci Rep. 2025 May 16;15(1):16985. doi: 10.1038/s41598-025-01877-4.
7
Pulmonary Hypertension-Related Interstitial Lung Disease: An Expert Opinion with a Real-World Approach.肺动脉高压相关间质性肺疾病:基于真实世界方法的专家意见
Biomedicines. 2025 Mar 27;13(4):808. doi: 10.3390/biomedicines13040808.
8
Lung function and nonalcoholic fatty liver disease: a Mendelian randomization study.肺功能与非酒精性脂肪性肝病:一项孟德尔随机化研究。
Arch Med Sci. 2023 Jun 27;21(1):197-205. doi: 10.5114/aoms/168475. eCollection 2025.
9
Fibrosis: cross-organ biology and pathways to development of innovative drugs.纤维化:跨器官生物学与创新药物研发途径
Nat Rev Drug Discov. 2025 Mar 18. doi: 10.1038/s41573-025-01158-9.
10
An exploratory analysis of differences in serum protein expression by sex in patients with systemic sclerosis associated interstitial lung disease.系统性硬化症相关间质性肺疾病患者血清蛋白表达性别差异的探索性分析。
BMC Pulm Med. 2025 Jan 13;25(1):16. doi: 10.1186/s12890-024-03474-z.